Compare MXL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MXL | TGTX |
|---|---|---|
| Founded | 2003 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.5B |
| IPO Year | 2009 | 2008 |
| Metric | MXL | TGTX |
|---|---|---|
| Price | $91.97 | $55.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $41.67 | ★ $49.80 |
| AVG Volume (30 Days) | ★ 3.3M | 2.6M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 46.08 | ★ 1746.67 |
| EPS | N/A | ★ 0.12 |
| Revenue | ★ $478,596,000.00 | $2,785,000.00 |
| Revenue This Year | $22.10 | $49.08 |
| Revenue Next Year | $10.70 | $26.69 |
| P/E Ratio | ★ N/A | $463.75 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.77 | $25.37 |
| 52 Week High | $128.30 | $59.30 |
| Indicator | MXL | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 60.89 |
| Support Level | $74.01 | $28.57 |
| Resistance Level | $105.27 | $57.38 |
| Average True Range (ATR) | 11.69 | 2.39 |
| MACD | -1.63 | -0.42 |
| Stochastic Oscillator | 27.41 | 51.84 |
MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.